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The inflammatory response to these bacteria is mediated by Toll-like receptors. The
Asp299Gly polymorphism of the Toll-like receptor-4 (TLR4) has been shown to be
associated with decreased lipopolysaccharide (LPS) signal transduction resulting in
impaired antimicrobial defense. Because altered TLR4 signalling may facilitate
bacterial infection, we clinically phenotyped and genotyped 152 patients with COPD
(including 24 non-smokers), and 444 healthy controls for the presence of the
Asp299Gly polymorphism. Frequencies of the TLR4 Gly allele (4% vs. 8% in controls,
odds ratio (OR) 2.24 (95% confidence interval (95%CI) 1.17–4.3)) as well as TLR4 Gly
genotype (6% vs. 13% in controls, OR 2.39 (95%CI 1.20–4.79)) were significantly
decreased among the patients with COPD. The TLR4 Gly allele was not detected at
all in a subgroup of non-smoking patients (n ¼ 24). We conclude that the frequency
of the Asp299Gly polymorphism is decreased in COPD patients. Unaltered LPS signal
transduction by TLR4 may be important for the development of COPD.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserve
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Chronic obstructive pulmonary disease (COPD) is a
major cause of death and morbidity worldwide,1
and it is believed to rank fifth as a worldwide
burden of disease in 2020.2 COPD is defined by
progressive development of irreversible airflow
limitation typically determined by reductions ind.
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tory volume at 1 s (FEV1) and the ratio of FEV1 to
forced vital capacity (FVC, FEV1/FVC).
3 The current
understanding of the pathogenesis includes a
complex interaction between environmental fac-
tors and genetic predisposition. One important
environmental risk factor for developing COPD is
cigarette smoke. However, only up to approxi-
mately half of chronic heavy smokers develop
significant airway obstruction.4,5 Another impor-
tant factor in the pathogenesis of COPD are
recurrent infections of the lower bronchial tree
with different bacteria6 and viruses.7,8 The most
common bacteria isolated are non-typeable Hae-
mophilus influenzae, Streptococcus pneumoniae
and Moraxella catarrhalis. The recognition of these
pathogens is facilitated by Toll-like receptors
(TLRs).9 They recognize pathogen-associated mo-
lecular patterns (PAMP) and activate signal-trans-
duction pathways that induce the expression of a
variety of immune-response genes, including in-
flammatory cytokines.10
It has been shown in family and in twin studies
that genetic predisposition may play a role in the
pathogenesis of COPD.11 Moreover an increased risk
to relatives of early onset COPD subjects for
reduced FEV1 and chronic bronchitis has been
described12 suggesting genetic risk factors for COPD
that are expressed in response to cigarette smok-
ing. The only proven genetic risk factor for COPD so
far is a1-antitrypsin deficiency, but the underlying
mutations are only found in about 1% of COPD
patients. Therefore, further genes are supposed to
play a crucial role in the predisposition to COPD.13
The Asp299Gly polymorphism of the TLR4 seems to
be a promising target as it has been shown to be
associated with decreased LPS signal transduction14
by affecting the extracellular domain of TLR4.
Moreover this mutation in the TLR4 gene may
predispose people to develop septic shock with
Gram-negative microorganisms,15 organisms which
are also found in advanced COPD.16 The carriers of
the Asp299Gly genotype have reduced levels of
proinflammatory cytokines, acute phase reactions,
soluble adhesion molecules, and an increased risk
of severe infections.17 The aim of this study was
therefore to investigate a possible association
between the Asp299Gly polymorphism of the TLR4
and the COPD phenotype.Patients
Hospitalized patients with COPD were recruited in a
600-bed University hospital in Bochum/Germany.COPD and its stages were defined according to the
Global Initiative for Chronic Obstructive Lung
Disease (GOLD) criteria.3 Patients were included
when they suffered from cough, sputum production
and dyspnea at least upon exertion and showed
chronic irreversible airflow limitation defined by a
FEV1/FVCo70% and a FEV1o80% of the predicted
value for age and height and b2-agonist reversibility
on predicted FEV1 of less than 15% and/or 200mL.
The following parameters were recorded: age,
gender, smoking habits and pulmonary function
testing.
Smoking habit was defined as follows: non-
smokers had never smoked; ex-smokers had smoked
daily and given it up prior to entering the study;
and smokers smoked daily at the time of study. The
amount of lifetime smoking was assessed as pack-
years (years of smoking number of packs of 20
cigarettes per day).
Spirometry was performed as described before.8
Briefly, the best out of three trials was selected and
data were compared to reference values.18 FEV1,
FVC and inspiratory vital capacity (IVC) were
assessed. Reversibility of airflow limitation was
tested 20min after inhalation of two puffs of
salbutamol (200 mg) by reassessing spirometry.
Blood samples of 152 patients with COPD were
collected. 444 ethnically matched healthy blood
donors recruited in Hamburg served as controls as
described previously.19 The climate and population
migration patterns of Bochum, Hamburg and their
respective surroundings are similar. The study was
approved by the Ethical Committee of the Ruhr-
University of Bochum, Germany. Written informed
consent was obtained from all subjects before
inclusion into the study.Materials and methods
PCR
Genomic DNA was extracted from EDTA-anticoagu-
lated blood according to Miller and colleagues.20
Primers TLR4 F (50-ggtttagaagtccatcgtttg-30) and
TLR4 R (50-ctgaaacaattaaataagtcaatagta-30; a mis-
match (bold letter) was introduced to create a
restriction site for the endonuclease Rsa I for the
Gly allele) were used to amplify a 170 bp fragment.
A 10 ml PCR amplification mixture containing 50 ng
DNA, 1U Taq polymerase (Genecraft), 0.2mmol of
each nucleotide, 1mM MgCl2 in 500mM KCl and
100mM Tris–HCl (pH 8.3) was run in a Thermocycler
(Trio-Block, Biometra). After two initial cycles at 62
and 59 1C annealing temperature, 25 cycles of
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run 0.5, 1 and 1min, respectively.RFLP analysis
The Gly allele of the polymorphism contains the
restriction site for Rsa I which is not present in the
Asp allele. The PCR products were restricted with
Rsa I and the resulting fragments (170 bp for the
Asp; 144 bp and 26 bp for the Gly allele, respec-
tively) were separated on 2% agarose gels and
stained with ethidium bromide.Statistics
The primary objective of this study was to compare
allele and genotype frequencies in healthy control
subjects and patients with COPD. For this compar-
ison the w2 method was used and Odds Ratios (OR)
and the 95% confidence interval (95%CI) of the OR
were calculated. The Yates correction procedure
was applied to all comparisons. All significanceTable 1 Characteristics of COPD patients.
All COPD Non-
smoking
COPD
P-value
(ANOVA)
No. 152 24 n.d.
Age 67.2710.1 69.379.6 0.492
Gender #97 ~56 #7 ~18 0.421
Pack years 32.5731.6 0 0.003
FEV1
[%pred.]
49.8721.3 65.7724.2 0.002
Differences between groups were assessed by univariate
analysis of variance (ANOVA).
Table 2 Allele and genotype frequencies of the Gly199
COPD and healthy controls.
Allele frequencies
Asp G
n % n
All COPD patients (n ¼ 152) 293 96 1
Non-smoking COPD patients (n ¼ 24) 48 100
Controls (n ¼ 444) 819 92 6
Genotype frequencies of the control samples are in Hardy–Weinbe
8% in controls, OR 2.24 (95%CI 1.17–4.3)) as well as TLR4 Gly geno
significantly decreased among the patients with COPD. In 24/152 o
not detected at all (P ¼ 0:045 for both, allele frequency and genlevels were set to 5%. Continuous data were checked
for normal distribution by the modified Kolmogor-
ov–Smirnov-test (Lilliefors). Parametric data were
expressed as mean and standard deviation, non-
parametric data as median and range [minimum to
maximum]. Differences between groups were
assessed by univariate analysis of variance (ANOVA).
The distributions of homozygotes and heterozy-
gotes in patients and control subjects were in
Hardy–Weinberg equilibrium. Data were analysed
and processed on SPSS Version 10.0 on a Windows
98 operating system.Results
A total of 152 COPD patients were included into the
final analysis. The clinical characteristics are given
in Table 1.
We have genotyped the Asp299Gly polymorphism
of the TLR4 gene by RFLP analysis. Frequencies of
the TLR4 Gly allele (4% vs. 8% in controls, OR 2.24
(95%CI 1.17–4.3)) as well as TLR4 Gly genotype (6%
vs. 13% in controls, OR 2.39 (95%CI 1.20–4.79))
were significantly decreased among the patients
with COPD (Table 2).
In a subanalysis, 24/152 of the COPD patients had
never smoked (16%, P ¼ 0:003). These patients had
a significantly better FEV1 in %predicted (P ¼ 0:002)
adjusted for age and gender and the Gly allele was
not detected at all (P ¼ 0:045 for both, allele
frequency and genotype; see Table 2).Discussion
The prevalence of the Gly299 allele was 8% in
normal controls and 4% in patients with COPD. ThisAsp polymorphism in the TLR4 gene in patients with
Genotype
ly Asp/Asp Asp/Gly Gly/Gly
% n % n % n %
1 4 142 93 9 6 1 1
0 0 24 100 0 0 0 0
9 8 380 86 59 13 5 1
rg proportion. The frequencies of the TLR4 Gly allele (4% vs.
type (6% vs. 13% in controls, OR 2.39 (95%CI 1.20–4.79)) were
f the COPD patients who had never smoked the Gly allele was
otype).
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COPD who had never smoked, patients who had
significantly better lung function than the rest of
the COPD group.
The TLR4 is involved in host response to LPS and
thus exposure to Gram-negative bacteria. The
Asp299Gly TLR4 polymorphism leads to a blunted
response to LPS and has been shown to be
associated with unfavourable outcome in e.g.
sepsis.15 Moreover, the polymorphism has been
shown to also affect TLR4-mediated LPS signalling
in primary human airway epithelial cells.21 In the
study presented here we found the frequency of
the Gly299 allele to be decreased in a cohort of
patients with COPD, when compared to an epide-
miologically drawn sample. This finding supports
the hypothesis that the inflammatory response to
bacterial challenges may be associated with the
development of COPD. The polymorphism impairing
hosts’ antibacterial response was found less fre-
quently in COPD patients and therefore the
increased inflammation observed in the airways of
these patients might in part be a result of an
unimpaired response to bacterial stimuli.
One might argue that both groups were not
drawn from the same sample, which is a potential
limitation of this study. Lung function could not be
assessed in the control sample and although the
control individuals were healthy blood donors, it
cannot be ruled out that some of these individuals
may develop COPD in later life. But altered allele
and genotype frequencies would cause a conserva-
tive mistake rather underestimating the underlying
association.
We found the Gly allele of the Asp299Gly
polymorphism to be completely absent in the
subgroup of patients with COPD who had never
smoked. Etiological factors leading to COPD in non-
smoking subjects are not well understood. Besides
the accepted environmental and occupational
factors the absence of the Asp299Gly polymorphism
could have additional impact in this type of
patients. This finding suggests importance of
genetic disposition as a possible contributor to
COPD development, but also underlines the im-
portance of the interaction between genetic dis-
position and cigarette smoking for the severity of
the disease.
There is only very limited literature regarding
the Asp299Gly polymorphism and COPD. Very
recently Sabroe et al. screened a population of
smokers (289 subjects) recruited on the basis of age
440 and smoking history of at least 10 pack years
for the presence of the Asp299Gly TLR4 polymorph-
ism. A total of 260 patients were Asp299 homo-
zygotes and 29 heterozygotes (11%) without anydetected Gly299 homozygotes. The presence of the
TLR4 polymorphism did not seem to be associated
with lung function in this study.22 These data seem
to partially contradict our data but it has to be
taken into account that this study investigated
selected patients, only. These authors did not study
patients with COPD but only smokers above a
certain age. No details about clinical symptoms
defining COPD are given and the authors avoid
describing their patients as COPD patients. We
investigated patients with established COPD and
found a significant reduction in the frequency of
the polymorphism. Looking at this study and our
own data and considering especially the relatively
low number of non-smoking COPD patients it
becomes clear that further studies investigating
much larger cohorts of COPD patients are needed to
draw final conclusions on the importance of the
Asp299Gly TLR4 polymorphism. However the OR of
2.24 for the detection of the Gly allele clearly
shows a significant difference between normal
controls and patients with COPD. Nevertheless the
95%CI ranges from 1.17–4.3, indicating the possibi-
lity of a rather weak effect.
In summary, this is the first study showing
relevance of the Asp299Gly polymorphism of the
TLR4 gene in COPD. The Gly allele and Gly
genotypes are found less frequently in these
patients suggesting that unaltered LPS signal
transduction by TLR4 may be important for the
development of COPD.References
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